Text adapted from: "The adult patient with a personality disorder," in Psychiatry in primary care by Michael Rosenbluth, Matthew Boyle & Lucille Schiffman (CAMH, 2019).
For primary care practitioners
National Education Alliance for Borderline Personality Disorder Information for clinicians and people with BPD, includes a free video series for professionals.
I Hate You—Don’t Leave Me: Understanding the Borderline Personality, by Jerold J. Kreisman and Hal Straus, TarcherPerigee, 2010.
Loving Someone with Borderline Personality Disorder: How to Keep Out-of-Control Emotions from Destroying Your Relationship, by Shari Y. Manning, Guilford Press, 2011.
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
Baldessarini, R.J., Tondo, L. & Davis, P. (2006). Decreased risk of suicides and attempts during long-term lithium treatment: A meta-analytic review. Bipolar Disorders, 8, 625–639.
Biskin, R. (2015). The lifetime course of BPD. Canadian Journal of Psychiatry, 60, 303–308.
Black, D.W., Zanarini, M.C., Romine, A., Shaw, A., Allen, J. & Schulz, S.C. (2014). Comparison of low and moderate dosages of extended release quetiapine in borderline personality disorder: A randomized, double blind, placebo-controlled trial. American Journal of Psychiatry, 171, 1174–1182.
Bozzatello, P., Brignolo, E., Grandi, E.D. & Bellino, S. (2016). Supplementation with omega-3 fatty acids in psychiatric disorders: A review of literature data. Journal of Clinical Medicine, 5, 67.
Canadian Agency for Drugs and Technologies in Health. (2017). Aripiprazole for Borderline Personality Disorder: A Review of the Clinical Effectiveness. Ottawa, ON: Author.
Cipriani, A., Pretty, H., Hawton, K. & Geddes, J.R. (2005). Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: A systematic review of randomized trials. American Jour- nal of Psychiatry, 162, 1805–1819.
Cowdry, R.W. (1992). Psychobiology and psychopharmacology of borderline personality disorder. In D. Silver & M.B. Rosenbluth (Eds.), Handbook of Borderline Disorders (pp. 495–509). Madison, CT: International Universities Press. Crawford, M., Sanatini, R., Barnett, B., Cunningham, G., Dale, O., Ganguli,
P LABILE Study Team. (2018). The clinical effectiveness and cost effectiveness of lamotrigine in borderline personality disorder: A randomized clinical study. American Journal of Psychiatry 175, 756–764.
Frances, A. (2005). Personality disorders. In K.R.R. Krishnan (Ed.), Educational Review Manual in Psychiatry (pp.1–34). New York, NY: Castle Connolly Graduate Medical Publishing.
Gunderson, J. G. & Choi-Kain, L.W. (2018). Medication management for patients with borderline personality disorder. American Journal of Psychiatry, 175, 709–711.
Gunderson, J.G., Stout, R.L., Shea, M.T., Grilo, C.M., Markowitz, J.C., Morey, L.C. & Skodol, A.E. (2014). Interactions of borderline personality disorder and mood disorders over 10 years. Journal of Clinical Psychiatry, 75, 829–834.
Gunderson, J.G., Weinberg, I., Daversa, M., Kueppenbender, K.D., Zanarini, M.C., Shea, T Dyck, I. (2006). Descriptive and longitudinal observations on the relationship of borderline personality disorder and bipolar disorder. American Journal of Psychiatry, 163, 1173–1178.
Gutheil, T.G. & Alexander, V. (1992). Medicolegal issues between the Borderline patient and the therapist. In D. Silver & M.B. Rosenbluth (Eds.), Handbook of Borderline Disorders (pp. 335–389). Madison, CT: International Universities Press.
Herpertz, S.C., Zanarini, M., Schulz, C.S., Siever, L., Lieb, K., Möller, H. & WFSBP Task Force on Personality Disorders. (2007). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World Journal of Biological Psychiatry, 8, 212–244.
Kaess, M., Brunner, R. & Chanen, A. (2014). Borderline personality disorder in adolescence. Pediatrics, 134, 782–793.
Kool, S., Schoevers, R., de Maat, S., Van, R., Molenaar, P., Vink, A. & Dekker, J. (2005). Efficacy of pharmacotherapy in depressed patients with and with- out personality disorders: A systematic review and meta-analysis. Journal of Affective Disorders, 88, 269–278.
Linehan, M.M. (1992). Behaviour therapy, dialectics and the treatment of borderline personality disorder. In D. Silver & M.B. Rosenbluth (Eds.), Handbook of Borderline Disorders (pp. 389–415). Madison, CT: International Universities Press.
Mulder, R.T. (2002). Personality pathology and treatment outcome in major depression: A review. American Journal of Psychiatry, 159, 359–371.
Ripoll, L.H. (2012). Clinical psychopharmacology of borderline personality disorder. Current Opinion in Psychiatry, 25, 52–58.
Ripoll, L.H. (2013). Neuroimaging and borderline personality disorder. Dialogues in Clinical Neuroscience, 15, 213–224.
Rosenbluth, M., MacQueen, G., McIntyre, R.S., Beaulieu, S. & Schaffer, A. (2012). The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders. Annals of Clinical Psychiatry, 24, 56–68.
Roy, A.K., Lopes, V. & Klein, R.G. (2014). Disruptive mood dysregulation disorder: A new diagnostic approach to chronic irritability in youth. American Journal of Psychiatry, 171, 918–924.
Stoffers, J.M. & Lieb, K. (2015). Pharmacotherapy for borderline personality disorder: Current evidence and recent trends. Current Psychiatry Reports, 17, 534.
Wasylyshen, A. & Williams, A.M. (2016). Second-generation antipsychotic use in borderline personality disorder: What are we targeting? Mental Health Clinician, 6, 82–88.
Yashimatsu, K. & Palmer, B. (2014). Depression in patients with borderline personality disorder. Harvard Review of Psychiatry, 22, 266–273
Zanarini, M.C., Frankenburg, F.R., Dubo, E.D., Sichel, A.E., Trikha, A., Levin, A. & Reynolds, V. (1998). Axis I comorbidity of borderline personality disorder. American Journal of Psychiatry, 155, 1733–1739.
Zanarini, M.C., Frankenburg, F.R., Hennen, J., Reich, D.B. & Silk, K. (2004). Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. American Journal of Psychiatry, 161, 2108–2114.
About the Authors
Michael Rosenbluth, MD, FRCPC,Chief, Department of Psychiatry, Michael Garron Hospital / Toronto East Health Network; associate professor, Department of Psychiatry, University of Toronto, Toronto, ON
Matthew Boyle, BSc, MD, FRCPC Lecturer, Department of Psychiatry, University of Toronto; staff psychiatrist, Sunnybrook Health Sciences Centre, Toronto, ON
Lucille Schiffman, DO candidate, Department of Medicine, Touro University California, Vallejo, CA